Wall Street analysts expect Zimmer Biomet Holdings Inc (NYSE:ZBH) to report earnings of $1.87 per share for the current fiscal quarter, according to Zacks Investment Research. Ten analysts have provided estimates for Zimmer Biomet’s earnings, with the lowest EPS estimate coming in at $1.83 and the highest estimate coming in at $1.90. Zimmer Biomet posted earnings per share of $2.13 in the same quarter last year, which would indicate a negative year over year growth rate of 12.2%. The company is expected to announce its next quarterly earnings report on Thursday, April 26th.
On average, analysts expect that Zimmer Biomet will report full year earnings of $7.82 per share for the current fiscal year, with EPS estimates ranging from $7.68 to $8.25. For the next financial year, analysts expect that the company will post earnings of $8.37 per share, with EPS estimates ranging from $8.00 to $9.05. Zacks’ EPS calculations are an average based on a survey of research firms that follow Zimmer Biomet.
Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Tuesday, January 30th. The medical equipment provider reported $2.10 EPS for the quarter, meeting the Zacks’ consensus estimate of $2.10. The company had revenue of $2.07 billion during the quarter, compared to the consensus estimate of $2.03 billion. Zimmer Biomet had a net margin of 23.51% and a return on equity of 15.45%. Zimmer Biomet’s quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.14 EPS.
A number of analysts have commented on the stock. Cantor Fitzgerald reiterated a “buy” rating and issued a $140.00 price objective on shares of Zimmer Biomet in a report on Tuesday, January 30th. BMO Capital Markets reiterated a “buy” rating and issued a $144.00 price objective on shares of Zimmer Biomet in a report on Tuesday, January 30th. Morgan Stanley increased their price objective on shares of Zimmer Biomet from $140.00 to $150.00 in a report on Monday, January 29th. SunTrust Banks increased their price objective on shares of Zimmer Biomet to $142.00 and gave the company a “buy” rating in a report on Monday, January 29th. Finally, Needham & Company LLC raised their price target on shares of Zimmer Biomet from $144.00 to $155.00 and gave the stock a “strong-buy” rating in a report on Tuesday, January 30th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Zimmer Biomet presently has an average rating of “Buy” and an average price target of $141.67.
In related news, insider Bryan C. Hanson bought 25,077 shares of the company’s stock in a transaction that occurred on Tuesday, February 20th. The stock was purchased at an average price of $119.68 per share, for a total transaction of $3,001,215.36. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Chad F. Phipps sold 20,826 shares of Zimmer Biomet stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $115.95, for a total transaction of $2,414,774.70. The disclosure for this sale can be found here. 1.07% of the stock is currently owned by company insiders.
A number of institutional investors have recently bought and sold shares of ZBH. Janus Henderson Group PLC increased its holdings in Zimmer Biomet by 100.0% in the 2nd quarter. Janus Henderson Group PLC now owns 135,304 shares of the medical equipment provider’s stock valued at $17,372,000 after purchasing an additional 67,657 shares during the last quarter. Advisory Services Network LLC increased its holdings in Zimmer Biomet by 1.0% in the 2nd quarter. Advisory Services Network LLC now owns 3,690 shares of the medical equipment provider’s stock valued at $474,000 after purchasing an additional 37 shares during the last quarter. Lord Abbett & CO. LLC increased its holdings in Zimmer Biomet by 2.8% in the 2nd quarter. Lord Abbett & CO. LLC now owns 43,400 shares of the medical equipment provider’s stock valued at $5,573,000 after purchasing an additional 1,200 shares during the last quarter. Stokes & Hubbell Capital Management LLC acquired a new stake in Zimmer Biomet in the 3rd quarter valued at approximately $298,000. Finally, Shell Asset Management Co. increased its holdings in Zimmer Biomet by 61.3% in the 3rd quarter. Shell Asset Management Co. now owns 37,358 shares of the medical equipment provider’s stock valued at $3,756,000 after purchasing an additional 14,200 shares during the last quarter. Hedge funds and other institutional investors own 88.18% of the company’s stock.
Zimmer Biomet (NYSE:ZBH) traded up $0.06 during mid-day trading on Friday, reaching $118.74. 325,769 shares of the company’s stock were exchanged, compared to its average volume of 1,422,870. The firm has a market cap of $24,037.61, a P/E ratio of 13.26, a price-to-earnings-growth ratio of 2.08 and a beta of 1.08. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.83 and a current ratio of 1.52. Zimmer Biomet has a 12 month low of $108.03 and a 12 month high of $133.49.
The business also recently announced a quarterly dividend, which was paid on Monday, January 29th. Investors of record on Friday, December 29th were issued a $0.24 dividend. The ex-dividend date was Thursday, December 28th. This represents a $0.96 annualized dividend and a yield of 0.81%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 10.65%.
TRADEMARK VIOLATION WARNING: “Zimmer Biomet Holdings Inc (ZBH) Expected to Announce Earnings of $1.87 Per Share” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/02/22/zimmer-biomet-holdings-inc-zbh-expected-to-announce-earnings-of-1-87-per-share.html.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Get a free copy of the Zacks research report on Zimmer Biomet (ZBH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.